公开(公告)号：US20230235355A1

公开(公告)日：2023-07-27

申请号：US18000815

申请日：2021-06-05

Applicant: EpicentRx, Inc.

Inventor： Tony R. REID ,  Bryan T. ORONSKY

IPC: C12N15/86 ,  C07K14/165 ,  A61K9/00 ,  C07K16/10 ,  A61K39/12 ,  A61P31/14 ,  A61P35/00

CPC classification number: C12N15/86 ,  C07K14/165 ,  A61K9/0019 ,  C07K16/10 ,  A61K39/12 ,  A61P31/14 ,  A61P35/00 ,  A61K2039/5256

Abstract: The present disclosure relates to recombinant human adenoviruses engineered to express a structural protein of a coronavirus. The recombinant adenoviruses are suitable for active immunization against a coronavirus in a human subject. Additionally, immune globulin obtained from immunized human subjects is suitable for passive immunization of a coronavirus-infected human subject.

公开(公告)号：US11510901B2

公开(公告)日：2022-11-29

申请号：US16960444

申请日：2019-01-08

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Arnold Oronsky ,  Tony R. Reid

IPC: A61K31/66 ,  A61K31/397 ,  A61K31/19 ,  A61K33/24 ,  A61K33/26 ,  A61K9/00 ,  A61K45/06

Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OO1 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OO1 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β-rays, γ-rays, neutron radiation, or a combination thereof.

公开(公告)号：US20220125946A1

公开(公告)日：2022-04-28

申请号：US17575488

申请日：2022-01-13

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Bryan ORONSKY ,  Tony R. REID

IPC: A61K47/68 ,  C12N15/85 ,  A61P35/00 ,  A61K47/69 ,  C12N7/04 ,  A61K48/00 ,  C12N15/62 ,  C12N7/02 ,  C12N15/86

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

公开(公告)号：US20220054480A1

公开(公告)日：2022-02-24

申请号：US17223422

申请日：2021-04-06

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Jan Scicinski

IPC: A61K31/495 ,  A61K31/397 ,  A61K9/00 ,  A61K31/4745

Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

公开(公告)号：US20220016077A1

公开(公告)日：2022-01-20

申请号：US17186724

申请日：2021-02-26

Applicant: EpicentRx, Inc. ,  Northrop Grumman Systems Corporation

Inventor： Mark D. Bednarski ,  Susan Knox ,  Louis Cannizzo ,  Kirstin Warner ,  Robert Wardle ,  Stephen Velarde ,  Shoucheng Ning

IPC: A61K31/397 ,  A61K9/00 ,  A61N5/10 ,  C07D205/04

Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

公开(公告)号：US20200155625A1

公开(公告)日：2020-05-21

申请号：US16616146

申请日：2018-05-24

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: A61K35/761 ,  C12N7/00 ,  C12N15/86 ,  A61K39/395 ,  A61P35/00

Abstract: The invention relates to a recombinant adenovirus that expresses endostatin, angiostatin, or a combination of endostatin and angiostatin. The invention also relates to method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of (i) a recombinant adenovirus and (ii) an anti-angiogenic agent to treat the cancer in the subject.

公开(公告)号：US20190352669A1

公开(公告)日：2019-11-21

申请号：US16482049

申请日：2018-01-30

Applicant: EpicentRx, Inc.

Inventor： Tony R. Reid ,  Bryan T. Oronsky ,  Farah Hedjran ,  Christopher Larson

IPC: C12N15/86 ,  A61K35/761

Abstract: The invention provides, e.g., a recombinant virus comprising (i) a modified TATA box-based promoter, and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter and/or modified CAAT box-based promoter lacks a functional TATA box and/or CAAT box and permit selective expression of the gene in a hyperproliferative cell. The recombinant viruses can be used to treat cell proliferative diseases and disorders, including certain forms of cancer.

公开(公告)号：US20190307723A1

公开(公告)日：2019-10-10

申请号：US16069012

申请日：2017-01-11

Applicant: EpicentRx, Inc.

Inventor： Bryan T. Oronsky ,  Jan Scicinski ,  Scott Caroen

IPC: A61K31/397 ,  A61K35/14 ,  A61K9/00 ,  A61P35/00 ,  A61K47/10 ,  A61K47/18 ,  A61K31/727 ,  A61P35/02 ,  A61K31/194

Abstract: The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.

公开(公告)号：US10149832B2

公开(公告)日：2018-12-11

申请号：US14965062

申请日：2015-12-10

Applicant: EpicentRx, Inc. ,  Orbital ATK, Inc.

Inventor： Mark D. Bednarski ,  Susan Knox ,  Louis Cannizzo ,  Kirstin Warner ,  Robert Wardle ,  Stephen Velarde ,  Shoucheng Ning

IPC: C07D205/04 ,  A61N5/10 ,  A61K31/397 ,  A61K9/00

Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

公开(公告)号：US20180085346A1

公开(公告)日：2018-03-29

申请号：US15669403

申请日：2017-08-04

Applicant: EpicentRx, Inc. ,  Orbital ATK, Inc.

Inventor： Mark D. Bednarski ,  Susan Knox ,  Louis Cannizzo ,  Kirstin Warner ,  Robert Wardle ,  Stephen Velarde ,  Shoucheng Ning

IPC: A61K31/397 ,  A61K9/00 ,  A61N5/10 ,  C07D205/04

CPC classification number: A61K31/397 ,  A61K9/0019 ,  A61N5/10 ,  C07D205/04

Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.